Wed Feb 05 15:10:00 UTC 2025: **Increased Investor Interest in Hims & Hers Health (HIMS) Amidst Insider Stock Sales**

**New York, NY – March 8, 2024** – Hims & Hers Health, Inc. (NYSE: HIMS), a telehealth platform, saw significant activity in its stock recently, with several institutional investors increasing their holdings while insiders sold a substantial amount of shares.

Several institutional investors boosted their positions in HIMS during the recent quarter. Means Investment CO. Inc. increased its stake by 23.5%, now holding 50,040 shares valued at $1.21 million. Other notable increases include Raleigh Capital Management Inc. (up 1,100%), GAMMA Investing LLC (up 2,173.7%), Quest Partners LLC (up 22.6%), CWM LLC (up 21.4%), and Nisa Investment Advisors LLC (up 115.3%). Overall, institutional investors own 63.52% of HIMS stock.

However, this positive investor sentiment was offset by insider selling. Soleil Boughton sold 4,153 shares, reducing their holding by 2.51%, and CEO Andrew Dudum sold 33,513 shares, a 50.01% decrease in his ownership. In total, insiders sold 1,171,332 shares worth $34.18 million over the past ninety days. Corporate insiders currently hold 17.71% of the stock.

Despite the insider sales, HIMS stock price rose $3.01 to close at $41.94 on Tuesday, with a trading volume significantly exceeding its average. The company boasts a market capitalization of $9.16 billion. HIMS recently reported strong quarterly earnings, exceeding analyst expectations with $0.32 EPS and $401.56 million in revenue.

Analyst opinions on HIMS are mixed. While some firms, including BTIG Research and Morgan Stanley, issued buy ratings with target prices of $35.00 and $42.00 respectively, others like Citigroup downgraded the stock to a sell rating. The average analyst rating is currently a Hold, with a consensus price target of $25.13.

Hims & Hers Health connects consumers with healthcare professionals for various health needs. The company was founded in 2017 and is headquartered in San Francisco, CA.

Read More